Correlation Between Ikena Oncology and Inhibrx
Can any of the company-specific risk be diversified away by investing in both Ikena Oncology and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ikena Oncology and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ikena Oncology and Inhibrx, you can compare the effects of market volatilities on Ikena Oncology and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ikena Oncology with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ikena Oncology and Inhibrx.
Diversification Opportunities for Ikena Oncology and Inhibrx
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Ikena and Inhibrx is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Ikena Oncology and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Ikena Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ikena Oncology are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Ikena Oncology i.e., Ikena Oncology and Inhibrx go up and down completely randomly.
Pair Corralation between Ikena Oncology and Inhibrx
Given the investment horizon of 90 days Ikena Oncology is expected to generate 0.42 times more return on investment than Inhibrx. However, Ikena Oncology is 2.35 times less risky than Inhibrx. It trades about -0.03 of its potential returns per unit of risk. Inhibrx is currently generating about -0.04 per unit of risk. If you would invest 171.00 in Ikena Oncology on August 30, 2024 and sell it today you would lose (2.00) from holding Ikena Oncology or give up 1.17% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 95.65% |
| Values | Daily Returns |
Ikena Oncology vs. Inhibrx
Performance |
| Timeline |
| Ikena Oncology |
| Inhibrx |
Ikena Oncology and Inhibrx Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Ikena Oncology and Inhibrx
The main advantage of trading using opposite Ikena Oncology and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ikena Oncology position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.| Ikena Oncology vs. Edgewise Therapeutics | Ikena Oncology vs. Design Therapeutics | Ikena Oncology vs. Xilio Development | Ikena Oncology vs. Eliem Therapeutics |
| Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |